BIND Nanotherapy Shows Early Cancer Efficacy In The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong preclinical data for BIND-014, docetaxel-carrying particles engineered using BIND’s Accurin platform, translated into positive results against tumors not usually vulnerable to the cancer drug, the company reported at a late-breaker poster session of the American Association for Cancer Research annual meeting.
You may also be interested in...
Bind Lands Nanoparticle Development Deal With Pfizer
The nanoparticle biotech has signed an agreement with Pfizer to develop an undisclosed number of small molecules that will use the Accurins technology to make the particles easier to use in hard to treat diseases.
Stealth Ninja Nanoparticle Increases Uptake Of Imaging Agents And Drugs
Researchers have devised a tiny synthetic peptide that signals macrophages scavenging for foreign invaders in the body to ignore it and move on. The molecule can be attached to imaging agents, drugs, and biologics, increasing their uptake by shielding them from attack by the immune system.
Deals Of The Week: Shire/arGEN-X/Ethris, Evotec/Yale, Amgen/Bind Biosciences
GSK’s venture arm outlines its investment priorities, which involve changes to the biopharma business model.